Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555452 | 1.00 | MAPT (0.49) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL22472061 | 0.84 | KDM4E (0.43) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL10952795 | 0.83 | ALDH1A1 (0.41) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL29375021 | 0.83 | ALDH1A1 (0.41) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL9597648 | 0.83 | ALDH1A1 (0.41) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL19444177 | 0.81 | SMN1; SMN2 (0.48) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL20635358 | 0.81 | RAB9A (0.53) | MAPTRAB9ANPC1LMNAPOLB | |
| SCHEMBL22053915 | 0.81 | ALDH1A1 (0.40) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL2324287 | 0.81 | KMT2A (0.46) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL5462851 | 0.81 | TP53 (0.45) | MAPTSMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112898206-A | Preparation method of 5, 6-dimethylbenzimidazole | 河北凡博医药科技有限公司 | 2021-06-04 | — | — | CN | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-4861872-A | Alkyl-phenylcarbamate derivative of polysaccharide | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-29 | — | — | US | claimed |
| EP-0281951-A1 | Alkyl-phenylcarbamate derivative of polysaccharide | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-14 | — | — | EP | claimed |
| EP-3915994-B9 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-116655638-B | Deuterated PRMT5 inhibitors | 上海齐鲁制药研究中心有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116655638-A | Deuterated PRMT5 inhibitors | 上海齐鲁制药研究中心有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-112898206-A | Preparation method of 5, 6-dimethylbenzimidazole | 河北凡博医药科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-112898206-A | Preparation method of 5, 6-dimethylbenzimidazole | 河北凡博医药科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-4391953-A | Diene rubber compositions containing N,N'-dithioformanilide crosslinkers | MONSANTO COMPANY (US) | 1983-07-05 | — | — | US | disclosed |
| US-4228103-A | Effecting condensation of nitrohaloarene and formyl derivative of a primary aromatic amine with alkali metal hydroxide | MONSANTO COMPANY (US) | 1980-10-14 | — | — | US | disclosed |
| US-4209463-A | Promoting the formation of nitrodiarylamines from nitrohaloarenes, activated aryl amines and sodium carbonates | MONSANTO COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
| US-4196146-A | Making nitrodiarylamines from formyl derivatives of aromatic amines and nitrohaloarenes by admixing with certain aqueous salt solutions | MONSANTO COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4187248-A | FORMANILIDE | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4187249-A | COMPOUNDS OF POTASSIUM, CESIUM, OR RUBIDIUM | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4140716-A | Process for making an amide of formic acid and forming nitrodiarylamine therefrom | MONSANTO COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | MAPT 1762/4885SMN1; SMN2 595/4885RAB9A 1412/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | MAPT 1460/4885SMN1; SMN2 839/4885RAB9A 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.